Navigation Links
TrueBeam™ System for Non-Invasive Image-Guided Cancer Treatment Receives Shonin Approval
Date:6/15/2011

TOKYO, June 15, 2011 /PRNewswire/ -- Varian Medical Systems, Inc. (NYSE: VAR), the world's leading manufacturer of medical technology for treating cancer with radiotherapy, announced today it has received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market the TrueBeam™ system for image-guided radiotherapy and radiosurgery in Japan.  Designed for the treatment of lung, breast, prostate, head and neck, and other types of cancer, Varian's TrueBeam system was engineered from the ground up to treat tumors with great speed and accuracy — including tumors that move during treatment as the patient breathes in and out.

TrueBeam features a multitude of technical innovations that dynamically synchronize imaging, patient positioning, motion management, and treatment delivery. Applicable for all forms of advanced external-beam radiotherapy including image-guided radiotherapy and radiosurgery, intensity-modulated radiotherapy (IMRT), stereotactic body radiotherapy (SBRT) and RapidArc® radiotherapy, TrueBeam can deliver treatments with a dose delivery rate that is roughly twice the maximum output of conventional systems. This makes it possible to offer shorter treatment times for patients, potentially enabling clinics to treat more patients each day and to improve precision by leaving less time for tumor motion during dose delivery.

"Intelligent" automation further speeds treatments and makes the technology easier for clinicians to use, with an up to five-fold reduction in the number of steps needed for imaging, positioning and treating patients.  A standard intensity-modulated treatment that would typically take ten minutes can be completed in less than two minutes.  

More than 220 TrueBeam systems have now been ordered by treatment centers around the world, and more than 65 installations are completed or
'/>"/>

SOURCE Varian Medical Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Clinical Experts Detail How They Use Varians TrueBeam™ Technology to Improve the Precision and Speed of Cancer Treatments
2. Varian Medical Systems Introduces New TrueBeam™ System for Image-Guided Radiotherapy and Radiosurgery to Clinicians in Asia at AOCMP in Taipei, Taiwan
3. Varian Medical Systems to Exhibit TrueBeam™ System for Image-Guided Cancer Treatments and New Software Capabilities at ASTRO Meeting in San Diego
4. Exempla Saint Joseph Hospital Commences Treating Cancer Patients Using New TrueBeam™ System for High-Precision Image-Guided Radiotherapy and Radiosurgery
5. Varian Medical Systems to Exhibit New TrueBeam™ System for Image-Guided Radiotherapy at ChinaMed Exhibition in Beijing
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. CardioFocus Endoscopic Ablation System Earns CE Mark to Treat Atrial Fibrillation; US Clinical Investigation Underway
8. Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission
9. Syndicom SpineConnect Web Platform Chosen for Applied Spines Leg and Back Pain Clinical Trial of Its Stabilimax NZ(R) Dynamic Spine Stabilization System
10. Life Recovery Systems Receives European CE Mark Approval for Its ThermoSuit(R) System
11. New Topical Therapy Safely Treats Serious Skin Infections Without Systemic Side Effects
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... May 4, 2015 Former NASA scientist ... last week where he discussed Theradome™, the first portable ... The FOX segment shows firsthand how, via laser technology, ... loss solution that will not require surgery or medication.  ... at the base of the hair follicle, which is ...
(Date:5/4/2015)... MUNDELEIN, Ill. , May 4, 2015 ... , with live video and product demonstrations at the ... Radiology imaging equipment such as Kodak and Fuji Cr,s, ... be auctioned at the first event. Various imaging equipment ... www.RadiologyAuction.com . After years of buying ...
(Date:5/4/2015)... , May 4, 2015  Oncobiologics, Inc., a ... antibody (mAb) biosimilars, has completed the construction of ... headquarters in Cranbury, New Jersey ... facility is designed to utilize multiple technologies ... commercial scale.  Through the use of the latest ...
Breaking Medicine Technology:FOX News Features Theradome as the Take-Home Solution to Tackle Baldness 2RadiologyAuction Announces Event Starting On May 5th 2Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 2Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 3
... The U.S. Food and Drug Administration today is ... because the highest approved dose--80 milligram (mg)--has been associated ... particularly during the first 12 months of use. ... agency is recommending that simvastatin 80 mg be used ...
... Neurologix, Inc. (OTCBB: NRGX) announced today several new results ... its novel, investigational gene therapy NLX-P101 for the treatment ... presentation of study findings to the National Institutes of ... analysis of new data showed patients treated with NLX-P101 ...
Cached Medicine Technology:FDA Announces New Safety Recommendations for High-Dose Simvastatin 2FDA Announces New Safety Recommendations for High-Dose Simvastatin 3Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinson's Disease to Recombinant DNA Advisory Committee 2Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinson's Disease to Recombinant DNA Advisory Committee 3Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinson's Disease to Recombinant DNA Advisory Committee 4Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinson's Disease to Recombinant DNA Advisory Committee 5Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinson's Disease to Recombinant DNA Advisory Committee 6Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinson's Disease to Recombinant DNA Advisory Committee 7Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinson's Disease to Recombinant DNA Advisory Committee 8Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinson's Disease to Recombinant DNA Advisory Committee 9
(Date:5/4/2015)... 04, 2015 Takeda Pharmaceuticals Corp. has ... settle thousands of Actos lawsuits ( http://www.theactoslawsuitcenter.com/ ) ... risk that a patient will develop bladder cancer. According ... 95% of those eligible for the Actos settlement accept ... cancer cases currently pending in courts around the country, ...
(Date:5/4/2015)... Johnson & Wales University (JWU) held a ... academic center on Wednesday, April 22. , Johnson & Wales ... available by the re-alignment of Interstate-195. JWU’s new academic building, ... Chestnut streets in Providence, is scheduled to be completed in ... land the university purchased in 2012. , “It has long ...
(Date:5/4/2015)... 04, 2015 The American Telemedicine Association ... policy reports which identify gaps in coverage and reimbursement, ... issued the State Telemedicine Gaps Reports last September, many ... laws and regulations impact healthcare delivery in their state,” ... of state actions across the nation, ATA reevaluated the ...
(Date:5/4/2015)... Switzerland (PRWEB) May 04, 2015 ... “ The Importance of Data Integrity in a ... McDowall as guest presenter. This webinar will be ... (15:00 GMT). , Data integrity is a critical ... submitted to regulatory agencies. However, in recent years ...
(Date:5/4/2015)... 04, 2015 EY today announced that ... a finalist for the EY Entrepreneur Of The Year® ... awards program recognizes entrepreneurs who demonstrate excellence and extraordinary ... personal commitment to their businesses and communities. Mr. ... of independent judges. Award winners will be announced ...
Breaking Medicine News(10 mins):Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 2Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 3Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 2Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 3Health News:American Telemedicine Association Delivers New State Report Cards on Telemedicine 2Health News:American Telemedicine Association Delivers New State Report Cards on Telemedicine 3Health News:METTLER TOLEDO Announces Live Webinar on the Importance of Data Integrity in a GXP Regulated Laboratory 2Health News:EY announces Kit Check CEO and Co-founder Kevin MacDonald as an EY Entrepreneur Of The Year® 2015 Award finalist in the Greater Washington Region 2
... ,Stop wasting tax dollars on investigations, -- ... -- Three-fifths favor stripping stats and awards from ... As this year,s,Major League Baseball season-opener approaches, a ... close eye on steroid use among,professional athletes., ...
... Expects Filing of Restated Audited Financial Statements No Later Than ... April 14, 2008 - ... - Confirms 2008 Revenue Guidance -, WARSAW, Ind., March 27 ... the global,orthopedic device industry and other medical markets, today announced that,the filing of its ...
... GPRO ) announced today that the Company will ... of Molecular Diagnostics Roundtable,Conference" in New York on April ... is scheduled to be webcast live and may be ... Gen-Probe,s website,at http://www.gen-probe.com . The webcast will be ...
... 27 Radian Guaranty Inc., the,primary mortgage insurance ... ),announced today that mortgages originated under "stated income" ... for mortgage insurance. In a,message to clients this ... used to verify assets and income are appropriate,with ...
... Prevents return to work almost as often as physical ... -- Depression stops stroke victims from returning to work almost ... The study of 210 men and women, average age 55, ... of them returned to work within six months -- about ...
... UCLA used a high resolution technique to examine the genome, ... stem cell lines and found that while both lines could ... certain genes that could control such things as individual traits ... genome, which contains all the genes on 46 chromosomes, is ...
Cached Medicine News:Health News:Americans Guess One-Third of Professional Athletes on Performance Enhancing Drugs 2Health News:Americans Guess One-Third of Professional Athletes on Performance Enhancing Drugs 3Health News:Symmetry Medical Delays 10-K Filing to Complete Review 2Health News:Symmetry Medical Delays 10-K Filing to Complete Review 3Health News:Symmetry Medical Delays 10-K Filing to Complete Review 4Health News:Gen-Probe to Webcast Presentation at Leerink Swann Molecular Diagnostics Conference 2Health News:Radian Guaranty Inc. Eliminates 'Stated Income' and 'Stated Asset' Programs 2Health News:Radian Guaranty Inc. Eliminates 'Stated Income' and 'Stated Asset' Programs 3Health News:Radian Guaranty Inc. Eliminates 'Stated Income' and 'Stated Asset' Programs 4Health News:Depression After Stroke Can Be Debilitating 2Health News:UCLA researchers examine human embryonic stem cell genome 2Health News:UCLA researchers examine human embryonic stem cell genome 3
Reliavac® 400cc kits with siliconized PVC drain, Y-connector tube...
Reliavac® 100cc low suction evacuator kits with flat drains and Y-connector tubing...
Reliavac 100cc evacuators offer a more constant suction profile than silicone evacuators. 100cc capacity is easy for patient to carry. Bottom emptying port reduces chance of contamination....
Used in the peritoneal cavity to remove large volumes of thick exudate....
Medicine Products: